Benedetti L, Levin A A, Scicchitano B M, Grignani F, Allenby G, Diverio D, Lo Coco F, Avvisati G, Ruthardt M, Adamo S, Pelicci P G, Nervi C
Department of Histology and Medical Embryology, University La Sapienza, Rome, Italy.
Blood. 1997 Aug 1;90(3):1175-85.
The bcr1- and bcr3- promyelocytic leukemia/retinoic acid receptor alpha (PML/RAR alpha) are the two major fusion proteins expressed in acute promyelocytic leukemia (APL) patients. These proteins, which are present in different lengths of PML (amino acids 1-552 and 1-394, respectively), contain most of the functional domains of PML and RAR alpha, bind all-trans-retinoic acid (t-RA), and act as t-RA-dependent transcription factors. T-RA is an effective inducer of clinical remission only in patients carrying the t(15;17) and expressing the PML/RAR alpha products. However, in APL patients achieving complete remission with t-RA therapy the bcr3-PML/RAR alpha product has been found associated with a poorer prognosis than bcr1-PML/RAR alpha. In the present study we have investigated the structural and functional properties of the bcr3-PML/RAR alpha in comparison to the previously characterized bcr1-PML/RAR alpha. In particular, we have measured the binding properties of the two endogenous ligands t-RA and 9-cis-RA to both of these isoforms. T-RA binding analysis of nuclear and cytosolic extracts prepared from bcr3-PML/RAR alpha APL patients and from bcr3-PML/RAR alpha COS-1 transfected cells indicates that this protein is present only as high-molecular-weight nuclear complexes. Using saturation binding assays and Scatchard analyses we found that t-RA binds with slightly less affinity to the bcr3-PML/RAR alpha receptor than to bcr1-PML/RAR alpha or RAR alpha (Kd = 0.4 nmol/L, 0.13 nmol/L or 0.09 nmol/L, respectively). Moreover, two different high-affinity 9-cis-RA binding sites (Kd = 0.45 and 0.075 nmol/L) were detectable in the bcr3-PML/RAR alpha product but not in the bcr1-PML/RAR alpha product (Kd = 0.77 nmol/L). By competition binding experiments we showed that 9-cis-RA binds with higher specificity to the bcr3-PML/RAR alpha isoform than to the bcr1-PML/RAR alpha or RAR alpha. Consistent with these data, the binding of 9-cis-RA to the bcr3-PML/RAR alpha product resulted in increased transcriptional activation of the RA-responsive element (RARE) TRE, but not of the betaRARE, in transiently transfected COS-1 cells. These results provide evidence indicating that preferential retinoid binding to the different PML/RAR alpha products can be measured.
bcr1-和bcr3-早幼粒细胞白血病/维甲酸受体α(PML/RARα)是急性早幼粒细胞白血病(APL)患者中表达的两种主要融合蛋白。这些蛋白分别含有不同长度的PML(分别为氨基酸1-552和1-394),包含PML和RARα的大部分功能结构域,能结合全反式维甲酸(t-RA),并作为依赖t-RA的转录因子发挥作用。t-RA仅在携带t(15;17)并表达PML/RARα产物的患者中是临床缓解的有效诱导剂。然而,在接受t-RA治疗实现完全缓解的APL患者中,已发现bcr3-PML/RARα产物与比bcr1-PML/RARα更差的预后相关。在本研究中,我们研究了bcr3-PML/RARα与先前已表征的bcr1-PML/RARα相比的结构和功能特性。特别是,我们测量了两种内源性配体t-RA和9-顺式维甲酸(9-cis-RA)与这两种异构体的结合特性。对来自bcr3-PML/RARα APL患者和转染bcr3-PML/RARα的COS-1细胞制备的核提取物和胞质提取物进行t-RA结合分析表明,该蛋白仅以高分子量核复合物形式存在。使用饱和结合测定和Scatchard分析,我们发现t-RA与bcr3-PML/RARα受体的结合亲和力略低于与bcr1-PML/RARα或RARα的结合亲和力(Kd分别为0.4 nmol/L、0.13 nmol/L或0.09 nmol/L)。此外,在bcr3-PML/RARα产物中可检测到两个不同的高亲和力9-cis-RA结合位点(Kd = 0.45和0.075 nmol/L),而在bcr1-PML/RARα产物中未检测到(Kd = 0.77 nmol/L)。通过竞争结合实验,我们表明9-cis-RA与bcr3-PML/RARα异构体的结合特异性高于与bcr1-PML/RARα或RARα的结合特异性。与这些数据一致,在瞬时转染的COS-1细胞中,9-cis-RA与bcr3-PML/RARα产物的结合导致RA反应元件(RARE)TRE的转录激活增加,但βRARE未增加。这些结果提供了证据表明可以测量类视黄醇与不同PML/RARα产物的优先结合。